Diabetes Australia stands up for people with type 2 as Ozempic shortage hits Australia 3 June 2022 An unexpected surge in people using the type 2 diabetes medication, Ozempic, for weight loss has caused a nation-wide shortage. In response, Diabetes Australia wrote to the Therapeutic Goods Administration to encourage them to take steps to prioritise people with type 2 diabetes. Novo Nordisk Pharmaceuticals initially advised the TGA of the shortage, which then approved that overseas-registered products can be imported. However, global supply problems mean delivery of the medication may be delayed. Following the DA communication, health professionals have now been asked to prescribe and dispense Ozempic for only those adults living with type 2 diabetes. It’s being reported in the Australian media that social media platforms, especially TikTok, have been featuring people promoting Ozempic as an easy and effective weight-loss solution, driving up demand for the medication by people who do not live with diabetes. According to a joint statement from the TGA, Diabetes Australia, Novo Nordisk and other health organisations, people who use Ozempic to treat type 2 diabetes are encouraged to contact their pharmacy as early as possible to ensure access to the supplies arriving in Australia. “Do not wait until you run out (or are close to running out) of your medicine,” the statement advises. “During a medicine shortage, it is best to leave your prescription with your regular pharmacy or preferred pharmacy if you can. “This will allow your pharmacist to order for you and help you get the medicines you need.” To read the statement in full: https://www.tga.gov.au/alert/joint-statement-prioritisation-semaglutide-ozempic-supply-people-type-2-diabetes-during-shortage
News 18 December 2024 Ozempic supply to remain limited in 2025 Ozempic supply will continue to be limited until the end of 2025, according to the latest advice from Novo Nordisk,... Continue Reading
News 16 December 2024 InnoLet human insulin cartridge to be discontinued Novo Nordisk has advised that it will discontinue the Protaphane InnoLet human insulin (rys) 100 IU/mL injection multidose cartridge on... Continue Reading
News 12 December 2024 Expanded access to cheaper medicines for Australians living with type 2 diabetes Diabetes Australia thanks the Albanese Government for its decision to expand the Pharmaceutical Benefits Scheme (PBS) listings for Forxiga® and... Continue Reading